Merkel cell carcinoma in solid organ transplant recipients: prognosis and response to immunotherapy
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljaf304 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Tomoko Akaike und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Skin Neoplasms, Organ Transplantation, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research.
Abstract (Originalsprache)
Background
Merkel cell carcinoma (MCC) is an aggressive skin cancer with an increased risk of occurrence in immunocompromised patients, including solid organ transplant recipients (SOTRs). As the number of SOTRs rises worldwide, MCC cases in this population are also expected to increase. While anti-programmed cell death 1 ligand 1 (anti-PD-L1; also known as anti-programmed death ligand 1) immunotherapy generates durable tumour responses in ∼50% of immunocompetent (IC) patients with advanced MCC, its efficacy and safety in SOTRs remain uncertain as these patients have been excluded from most clinical trials.
Objectives
To compare baseline characteristics and outcomes among SOTRs and IC patients with MCC, and to evaluate the efficacy and toxicity of anti-PD-L1 in SOTRs.
Methods
We queried an MCC registry from our institution (April 1988–May 2024), extracting data on demographics, anti-PD-L1 response and immunosuppression regimens, along with incidence of allograft rejection and failure, for analysis.
Results
We identified 1214 patients with MCC (37 SOTRs and 1177 IC patients); 8 of 37 SOTRs received anti-PD-L1. Median time from SOT to MCC diagnosis was 10 years (range 0.4–43). The proportion of patients with advanced MCC (≥ stage III) was 76% in SOTRs compared with 51% in IC patients (P = 0.004). SOTR status was associated with worse outcomes, including higher rates of disease progression [adjusted hazard ratio (aHR) 2.3], MCC-specific mortality (aHR 3.0) and overall mortality (aHR 3.9) (all P < 0.001 for the respective comparisons). Median time to death due to MCC for SOTRs was 2.7 years; 24% of SOTRs died within one year of diagnosis, in contrast with just 4% of IC patients. Median time to MCC progression for SOTRs was 8.6 months vs. 12 years for IC patients. Among SOTRs, 70% developed distant metastases within 2 years vs. 25% of IC patients. All eight MCC SOTRs treated with anti-PD-L1 were kidney transplant recipients, with five (63%) experiencing an objective response (two complete response, three partial response). However, two patients (29%) experienced irreversible graft failure within 9 weeks.
Conclusions
SOTR status is a significant independent risk factor of a worse prognosis for MCC. This study represents the largest cohort evaluating the efficacy and safety of anti-PD-L1 in SOTRs with advanced MCC, highlighting the potential benefits in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Washington, Seattle, WA, USA.
- Albert Einstein College of Medicine, Bronx, NY, USA.
- Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Surgery, East Carolina University, Greenville, NC, USA.
- Department of Medicine, University of Washington, Seattle, WA, USA.
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
ORCID-Profile: Tomoko Akaike, Peter Y Ch'en, Daniel S Hippe, Christopher D Blosser, Paul Nghiem
Förderung
- NCI NIH HHS
- Bloomberg∼Kimmel Institute for Cancer Immunotherapy
- Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research
- Barney Family Foundation
- Laverna Hahn Charitable Trust
- National Institutes of Health/National Cancer Institute
Zitieren
APA
Akaike, T., Ch'en, P. Y., Hippe, D. S., Gilmour, M. W., Gong, E., Fu, A., Singh, N., Cahill, K., Gunnell, L., Vohra, N., Hall, E., Bhatia, S., Lipson, E. J., Blosser, C. D., & Nghiem, P. (2025). Merkel cell carcinoma in solid organ transplant recipients: prognosis and response to immunotherapy. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf304
Vancouver
Akaike T, Ch'en PY, Hippe DS, Gilmour MW, Gong E, Fu A, et al. Merkel cell carcinoma in solid organ transplant recipients: prognosis and response to immunotherapy. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf304
BibTeX
@article{Akaike2025,
author = {Akaike, Tomoko and Ch'en, Peter Y and Hippe, Daniel S and Gilmour, Macy W and Gong, Emily and Fu, Alex and Singh, Neha and Cahill, Kelsey and Gunnell, Lindsay and Vohra, Nasreen and Hall, Evan and Bhatia, Shailender and Lipson, Evan J and Blosser, Christopher D and Nghiem, Paul},
title = {Merkel cell carcinoma in solid organ transplant recipients: prognosis and response to immunotherapy},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljaf304}
}
EUVIMED